JP2023159309A5 - - Google Patents

Info

Publication number
JP2023159309A5
JP2023159309A5 JP2023134673A JP2023134673A JP2023159309A5 JP 2023159309 A5 JP2023159309 A5 JP 2023159309A5 JP 2023134673 A JP2023134673 A JP 2023134673A JP 2023134673 A JP2023134673 A JP 2023134673A JP 2023159309 A5 JP2023159309 A5 JP 2023159309A5
Authority
JP
Japan
Prior art keywords
nemolizumab
pharmaceutical composition
mobile phase
column
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023134673A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023159309A (ja
JP7812826B2 (ja
Filing date
Publication date
Priority claimed from JP2023501876A external-priority patent/JP7721630B2/ja
Application filed filed Critical
Publication of JP2023159309A publication Critical patent/JP2023159309A/ja
Publication of JP2023159309A5 publication Critical patent/JP2023159309A5/ja
Priority to JP2026012833A priority Critical patent/JP2026063423A/ja
Application granted granted Critical
Publication of JP7812826B2 publication Critical patent/JP7812826B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023134673A 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント Active JP7812826B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026012833A JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021207714 2021-12-22
JP2021207714 2021-12-22
JP2023501876A JP7721630B2 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023501876A Division JP7721630B2 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026012833A Division JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Publications (3)

Publication Number Publication Date
JP2023159309A JP2023159309A (ja) 2023-10-31
JP2023159309A5 true JP2023159309A5 (cg-RX-API-DMAC7.html) 2025-09-24
JP7812826B2 JP7812826B2 (ja) 2026-02-10

Family

ID=86902603

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2023501876A Active JP7721630B2 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント
JP2023134673A Active JP7812826B2 (ja) 2021-12-22 2023-08-22 生物活性が低下した抗体バリアント
JP2026012833A Pending JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023501876A Active JP7721630B2 (ja) 2021-12-22 2022-12-21 生物活性が低下した抗体バリアント

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026012833A Pending JP2026063423A (ja) 2021-12-22 2026-01-29 生物活性が低下した抗体バリアント

Country Status (7)

Country Link
US (1) US20250163163A1 (cg-RX-API-DMAC7.html)
EP (1) EP4455163A4 (cg-RX-API-DMAC7.html)
JP (3) JP7721630B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260007630A (cg-RX-API-DMAC7.html)
CN (1) CN118613503A (cg-RX-API-DMAC7.html)
TW (1) TW202340249A (cg-RX-API-DMAC7.html)
WO (1) WO2023120561A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2418220T (pt) * 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
ES2544888T3 (es) 2006-06-08 2015-09-04 Chugai Seiyaku Kabushiki Kaisha Prevención o remedio para enfermedades inflamatorias
TWI548418B (zh) 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
KR20260090008A (ko) * 2017-11-01 2026-06-16 추가이 세이야쿠 가부시키가이샤 생물 활성이 저하된 항체 배리언트 및 아이소폼
SG11202009629YA (en) * 2018-04-02 2020-10-29 Amgen Inc Erenumab compositions and uses thereof
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤

Similar Documents

Publication Publication Date Title
CN103288953B (zh) 一种血浆中功能性蛋白质的分离纯化方法
RU2610667C2 (ru) Способ очистки белков
JP5948343B2 (ja) トランスジェニックイネの子実からヒト血清アルブミンを精製する方法
JP6039550B2 (ja) タンパク質の精製装置および方法
JP7430012B2 (ja) アダリムマブのnon-protein a精製方法
CN111876393A (zh) 一种大规模快速生产高纯度高活性慢病毒载体的方法
JP2023537565A5 (cg-RX-API-DMAC7.html)
CN105669560A (zh) 一种从发酵液中分离提取四氢嘧啶的方法
CN103570820B (zh) 一种重组人促卵泡激素的纯化方法
IL194629A (en) Purification processes for isolation of pure vascular stomatitis from cell culture
JP7512891B2 (ja) ポリペプチドの分離方法、ポリペプチドの製造方法及びポリペプチドの精製装置
CN111304193A (zh) 一种大规模快速纯化质粒dna的方法
CN102174100A (zh) 多肽cw7213纯化工艺方法
TW201841933A (zh) 使用陽離子交換層析法純化同功抗體之方法
CN115894663A (zh) 一种重组人白细胞介素-2纯化方法
CN114645025A (zh) 一种人源atp合成酶的纯化方法
CN119371491B (zh) Pegcetacoplan的纯化方法和制备方法
TWI670278B (zh) 高純度低內毒素碳水化合物(hple)組合物及其分離方法
TW201900257A (zh) 使用親和力層析術純化抗體或其抗體片段的方法
JP2012214408A (ja) 澄明液中に分散した不純物凝集体を除去することによるタンパク質の精製方法
CN102286069A (zh) 一种有机溶剂沉淀分离初步提纯谷胱甘肽发酵液的方法
AU2019242986B2 (en) Bordetella pertussis-derived protein-obtaining method including affinity chromatography process
KR20250011797A (ko) 알부민이 융합된 단백질의 정제방법
CN116874446A (zh) 一种3-(n-吗啉基)-2-羟基丙磺酸钠合成工艺
CN119019522A (zh) 一种纯化齐考诺肽的方法